PR Newswire Clinical TrialsOriginal article
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
Phase 3LAM561Positive
AI Analysis
Summary
Laminar Pharma announced completion of last patient last visit in its Phase 2b/3 clinical trial of LAM561 for newly diagnosed glioblastoma patients. The trial milestone marks progress toward data readout, though no efficacy results have been disclosed.
Clinical Trial Data
Phase
Phase 2b/3
Outcome Details
Last patient last visit completed in Phase 2b/3 trial
Importance:6/10
Sentiment:
0.30
glioblastomaoncologyclinical trialmembrane lipid therapyLPLV milestone
Read the original article
Published by PR Newswire Clinical Trials on July 24, 2026 1:30 AM